1. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1014,
1995,
Page 2-2
&NA;,
Preview
|
PDF (1157KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
2. |
Benefits of pravastatin extend to primary prevention of CHD |
|
Inpharma Weekly,
Volume &NA;,
Issue 1014,
1995,
Page 3-4
Sean Henahan,
Preview
|
PDF (2116KB)
|
|
摘要:
Lowering cholesterol levels in men who have hypercholesterolaemia but no symptoms of cardiovascular disease can significantly reduce the risk of developing coronary heart disease (CHD), according to the results of the first major study of an HMG-CoA reductase inhibitor in primary prevention. The results of this landmark trial, which is referred to as the West of Scotland Coronary Prevention Study (WOSCOPS), were presented at the 68th Scientific Sessions of the American Heart Association [Anaheim, US; November 1995], and have also been published in a recent issue of theNEJM.1
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
3. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1014,
1995,
Page 5-5
&NA;,
Preview
|
PDF (1043KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
4. |
Pharmacotherapy favoured over surgery for BPH |
|
Inpharma Weekly,
Volume &NA;,
Issue 1014,
1995,
Page 6-6
&NA;,
Preview
|
PDF (1044KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
5. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1014,
1995,
Page 7-7
&NA;,
Preview
|
PDF (946KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
6. |
Controversy surrounds SCH-39166 in schizophrenia |
|
Inpharma Weekly,
Volume &NA;,
Issue 1014,
1995,
Page 8-8
&NA;,
Preview
|
PDF (1041KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
7. |
Safer NSAIDs? Selective COX-2 inhibitors may be the answer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1014,
1995,
Page 9-10
David B Jack,
Preview
|
PDF (2153KB)
|
|
摘要:
Several pharmaceutical companies are developing more selective cyclo-oxygenase (COX) inhibitors in an attempt to reduce the gastrointestinal (GI) and renal adverse effects seen with conventional NSAIDs. Two isoforms of cyclo-oxygenase exist - COX-1 and COX-2. Current research suggests that the GI and renal adverse effects of NSAIDs are due to inhibition of COX-1, while the therapeutic effects are due to COX-2 inhibition. This has prompted the search for COX-2—specific agents. The latest progress with this approach was presented at the Second World Congress on Inflammation [Brighton, UK; September 1995].
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
8. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1014,
1995,
Page 10-10
&NA;,
Preview
|
PDF (1044KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
9. |
Anticonvulsant drug level monitoring often inappropriate |
|
Inpharma Weekly,
Volume &NA;,
Issue 1014,
1995,
Page 11-11
&NA;,
Preview
|
PDF (1076KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
10. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1014,
1995,
Page 12-12
&NA;,
Preview
|
PDF (1068KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|